The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.878%)
Open: 42.00
High: 42.00
Low: 42.00
Prev. Close: 42.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Apr 2021 11:56

Cambridge Cognition shares up 21% after new GBP500,000 contract win

Cambridge Cognition shares up 21% after new GBP500,000 contract win

Read more
8 Apr 2021 11:24

AIM WINNERS & LOSERS: Minds + Machines up on USD120 million asset sale

AIM WINNERS & LOSERS: Minds + Machines up on USD120 million asset sale

Read more
30 Mar 2021 16:03

IN BRIEF: Cambridge Cognition wins contract for schizophrenia trial

IN BRIEF: Cambridge Cognition wins contract for schizophrenia trial

Read more
30 Mar 2021 13:56

Cambridge Cognition wins fourth schizophrenia trial contract

(Sharecast News) - Cambridge Cognition has won a £1.3m contract as the cognitive assessment partner for a schizophrenia trial, it announced on Tuesday.

Read more
23 Mar 2021 11:58

Cambridge Cognition shares surge as it eyes profitability in 2021

Cambridge Cognition shares surge as it eyes profitability in 2021

Read more
16 Mar 2021 15:53

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Jan 2021 13:45

Cambridge Cognition Sees "Significant" Revenue Growth During 2020

Cambridge Cognition Sees "Significant" Revenue Growth During 2020

Read more
21 Dec 2020 14:20

IN BRIEF: Cambridge Cognition Wins GBP700,000 Digital Health Contract

IN BRIEF: Cambridge Cognition Wins GBP700,000 Digital Health Contract

Read more
7 Oct 2020 18:20

UK TRADING UPDATE SUMMARY: Gym Group Fighting Fit With Fresh York Unit

UK TRADING UPDATE SUMMARY: Gym Group Fighting Fit With Fresh York Unit

Read more
22 Sep 2020 14:12

UK EARNINGS SUMMARY: IGas Swings Sharply To Loss As Revenue Halves

UK EARNINGS SUMMARY: IGas Swings Sharply To Loss As Revenue Halves

Read more
15 Sep 2020 15:53

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
14 Sep 2020 13:13

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

Read more
1 Sep 2020 16:22

Cambridge Cognition wins £2m contract with pharma firm

(Sharecast News) - Brain health company Cambridge Cognition has won a £2m contract as the cognitive assessment partner for three late-phase clinical trials for a pharmaceutical company's lead drug candidate for patients with schizophrenia, it announced on Tuesday.

Read more
1 Sep 2020 11:57

Cambridge Cognition Secures GBP2 Million Deal For Schizophrenia Trials

Cambridge Cognition Secures GBP2 Million Deal For Schizophrenia Trials

Read more
27 Jul 2020 17:58

UK EXECUTIVE CHANGE SUMMARY: Provident Financial Taps Former MP James

UK EXECUTIVE CHANGE SUMMARY: Provident Financial Taps Former MP James

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.